Division of Institut Merieux
Latest From Transgene SA
The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.
A late-phase assessment of the oncolytic virus in liver cancer patients was stopped early for futility but Transgene thinks the failure is an isolated event.
Oncolytic virus-based therapies which act as immune activators will be the only candidates in the Norwegian biotech’s pipeline from now on.
Goldfinch’s Kidney Genome Atlas may yield novel therapies for diabetic kidney disease and orphan renal indications, with Gilead holding option rights. Spectrum licenses IP from ImmunGene that could safely harness the potential of interferon therapy in cancer.
- Therapeutic Areas
- Hepatic (Liver)
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- Institut Merieux
- Senior Management
Philippe Archinard, PhD, Chmn. & CEO
Jean-Philippe Del, VP, Fin.
Thibaut du Fayet, PhD, VP, Alliance Mngmt., Project Mngmt. & Mktg.
Maud Brandely, MD, PhD, CMO
- Contact Info
Phone: (33) 3 88 27 91 00
400 Boulevard Gonthier d'Anderach
Illkirch Graffenstaden, F-67405
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.